Auditor's conclusion. 1125 N. Charles St, Baltimore, MD 21201. Illumina Inc s' competitors and its Market Share by segment - CSIMarket Nascent competition can include potential competition, but is a broader concept. Device. Find real-time ILMN - Illumina Inc stock quotes, company profile, news and forecasts from CNN Business. 300x250. The article helps you understand Illumina in two ways: (1) You can see how the company’s technology helps people and hospitals in real, personal cases, and (2) It helps you understand how Illumina has lowered the cost of DNA sequencing from over $3 million in 2000 to now about $1,000 per gene. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Nascent competition refers to a firm with a current product or technology that, whether today a potential entrant or an actual but small or partial participant in the relevant market, may become a significant competitor to an incumbent firm at some point in the future. Oct 09, 2019 to Nov 10, 2019 Illumina. Please reach out to our Investor Relations team at ir@illumina.com if you have questions. Awarded grant winners have the opportunity to spend one week at Illumina Accelerator in the San Francisco Bay Area to run proof-of-concept sequencing experiments. All rights reserved. As another way to dig a competitive moat, Illumina last fall agreed to buy smaller competitor Pacific Biosciences for $1.2 billion. San Diego-based Illumina, the world’s largest DNA sequencing company, powers everything from direct-to consumer tests to livestock breeding. Earnings for Illumina are expected to grow by 19.13% in the coming year, from $4.39 to $5.23 per share. Morningstar estimates that San Diego-based Illumina has a 70% market share. During its third-quarter report, Illumina announced a 6% year-over-year increase in revenues to $907 million. ... Illumina does have competitors. Here is what that means. Copyright © Auditor's conclusion. Oct 09, 2019 to Nov 10, 2019 Illumina. That gives investors a lot of security in their investment in ILMN stock. Price to Earnings Ratio vs. the Market. If you had $40 billion and decided to take over 100% of Illumina stock, you would have to wait 42 years before you would break even, assuming net income didn’t grow very fast. And on that note, ILMN stock’s P/E ratio is also sky high. Pacific Biosciences would bring an ability to decipher lengthier pieces of DNA, complementing Illumina’s technology that decodes DNA fragments. Its systems include the machinery and the software used to sequence pieces of DNA and RNA, as well as the means to put them through large-scale testing of genetic variation and biological function. The company generates revenue from sequencing tools and dedicated consumables (73% of 2019 sales). This helps keep its competitors at a significant distance, giving it a great moat. Merger. Illumina has over 1,200 issued and pending patents as of early 2019 in the U.S. It discusses how Illumina helped the parents of a young child with a rare and undiagnosed disease. Comparing the results to its competitors, Illumina Inc reported Total Revenue decrease in the 3 quarter 2020 year on year by -12.46 %, faster than overall decrease of Illumina Inc 's competitors by -12.46 %, recorded in the same quarter. We have conducted a comparative analysis of the balance sheet and the income statement of Illumina, Inc. (hereafter – the "Company") for the year 2019 submitted to the U.S. Securities and Exchange Commission (SEC). All content is posted anonymously by employees working at Illumina. Nearly one year after DNA sequencing machine maker Illumina announced plans to acquire smaller rival Pacific Biosciences, antitrust regulators in the UK say the merger could stifle competition … The company generates revenue from sequencing tools and dedicated consumables (73% of 2019 sales). Illumina has 7,700 employees across 16 locations and $3.54 B in annual revenue in FY 2019. SAN DIEGO--(BUSINESS WIRE)--Jul. Desktop. Published 24 October 2019 Brexit. Competitors, Alternatives, Traffic & 1 Marketing Contacts listed including their Email Addresses and Email Formats. Illumina is thought to have a worldwide next-generation sequencing market share of around 70%, and was boosted recently by Qiagen quitting the sequencing space (Storm-tossed Qiagen plots a course to higher growth, October 8, 2019). The competition: Who is Illumina’s new $100M startup, Grail, up against in cancer liquid biopsy screening? But I have already shown that net income only grew 5%. The company now expects to report Q2 revenue of … The primary business activity of the company is Laboratory Analytical Instruments (SIC code 3826). Device. illumina is the top-ranking maker of next-generation sequencing tools used by life sciences and drug researchers to isolate and analyze genes. Wired magazine recently published a very interesting story about Illumina. Desktop. Together they have raised over 5.3B between their estimated 365.8K employees. Completing the CAPTCHA proves you are a human and gives you temporary access to the web property. Nov 13, 2019 | staff reporter. Illumina Remains NGS Leader But Competitors Expected to Gain, Survey Finds. The Federal Trade Commission has authorized an action to block Illumina Inc.’s proposed $1.2 billion acquisition of Pacific Biosciences of California (PacBio). More importantly, Illumina’s free cash flow fell 4.4% year-over-year to $218 million. Device. Competition. Thursday, November 21, 2019. Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. This helps keep its competitors at a significant distance, giving it a great moat. The Commission alleges in an administrative complaint that Illumina is seeking to unlawfully maintain its monopoly in the U.S. market for next-generation DNA sequencing (NGS) systems by extinguishing PacBio as a nascent … The market values Illumina stock’s net income at over 42 times. Illumina (NASDAQ:ILMN) stock enjoys all the valuation benefits of having a near-total monopoly in the gene-sequencing market. Dates Active. Dimensions. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. ET by MarketWatch Automation PerkinElmer Inc. stock falls Tuesday, underperforms market Detailed Financial Results for Illumina. Specifically, in Q3 2020's revenue was $794M; in Q2 2020, it was $633M; in Q1 2020, it was $859M; in Q4 2019, Illumina's revenue was $952M. other. The P/E ratio of Illumina is 92.97, which means that it is trading at a more expensive P/E ratio than the market average P/E … • List of ILMN Competitors With net margin of 22.54 % company reported lower profitability than its competitors. Britain's competition watchdog said on Tuesday the planned $1.2 billion merger between gene sequencing company Illumina Inc and smaller rival Pacific Biosciences of California Inc may be a … This is the Illumina company profile. Desktop. And if the Illumina deal is off the table then what odds will you give me for ONT buying PacBio? Desktop. Illumina was founded in April 1998 by David Walt, Larry Bock, John Stuelpnagel, Anthony Czarnik, and Mark Chee.While working with CW Group, a venture-capital firm, Bock and Stuelpnagel uncovered what would become Illumina's BeadArray technology at Tufts University and negotiated an exclusive license to that technology. https://www.genengnews.com/a-lists/top-10-sequencing-companies-2 Just in time for the start of the JP Morgan conference, Roche and Illumina, the competitors in the emerging market of NGS-based cancer patient stratification and therapy decision support announced a long-term non-exclusive … Tweet. 2021 InvestorPlace Media, LLC. San Diego, California, Hilden, Germany and Germantown, Maryland - October 7, 2019 – Illumina, Inc. (NASDAQ: ILMN) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a 15-year partnership intended to broaden the availability and use of NGS-based in-vitro diagnostic (IVD) kits, including companion diagnostics, for patient management. ... Illumina Alternatives & Competitors Illumina, Inc. At Illumina, our goal is to apply innovative technologies and revol... (1 contacts listed) So growth is slowing. Illumina's revenue is the ranked 7th among it's top 10 competitors. Revenue ($ millions) $794. Illumina has 7,700 employees across 16 locations and $3.54 B in annual revenue in FY 2019. ... Illumina Alternatives & Competitors Illumina, Inc. At Illumina, our goal is to apply innovative technologies and revol... (1 contacts listed) Awarded grant winners have the opportunity to spend one week at Illumina Accelerator in the San Francisco Bay Area to run proof-of-concept sequencing experiments. But for the past 12 months, revenue grew only 1.6% to $3.6 billion. See insights on Illumina including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Nasdaq It’s nice that Illumina provides so much value in the medical field by lowering the cost of DNA sequencing. Mark Hake runs the Total Yield Value Guide which you can review here. More importantly, the free cash flow yield value for Illumina stock is 1.7%. Premium. Dimensions. 1125 N. Charles St, Baltimore, MD 21201. Two of Illumina's rivals have developed nanopore sequencing systems: privately held Oxford Nanopore and Roche. Article printed from InvestorPlace Media, https://investorplace.com/2019/11/dont-pay-high-price-illumina-stock/. Scenario No. The article really opens your eyes to the practical aspects of what DNA sequencing is all about. ... Illumina does have competitors. • List of ILMN Competitors With net margin of 22.54 % company reported lower profitability than its competitors. But Pounce on the Lucid Motors Merger, How the Internet Sent GameStop Stock Up 1,000% — And Where It’s Going Next, While It’s Holding Steady Now, Get Ready to Bail on Palantir Stock, CCIV Stock: Comparing Lucid Motors to Tesla as ‘Merger Monday’ Hopes Soar. BaseSpace Suite. Illumina has become dominant in the field of next-generation DNA sequencing by building machines that sequenced DNA more cheaply and rapidly than several competitors, many of … That’s down 1.4% on a 12-month basis to $691 million from the prior quarter. The Illumina Accelerator Sequencing Grant Competition encourages entrepreneurs to build startups using next-generation sequencing. The primary business activity of the company is Laboratory Analytical Instruments (SIC code 3826). ET by MarketWatch Automation PerkinElmer Inc. stock falls Tuesday, underperforms market Jan 05, 2018 | Julia Karow. And it’s nice that there is very little competition. Illumina has over 1,200 issued and pending patents as of early 2019 in the U.S. Our earnings reports, supplementary data, 10Q and 10K, and selected other documents are available below by quarter. $907-12%. The British CMA is blocking the merging of @illumina and @PacificBio not to keep the market competitive, but to eliminate Picific Bio so the British company Nanopore will dominate the long sequencing field. Illumina is committed to data security. But you pay a very high price for that security. Dimensions. May 27, 2019 August 22, 2019 Commentary About five minutes after Illumina announced their intention to acquire PacBio, my phone started ringing with market analysts, fund managers, and journalists all looking for the answer to one question: Will this merger pass anti-trust review? Nevertheless, newcomers such as China’s BGI and the UK’s Oxford Nanopore have the potential to change this along with other technologies in development, some of which might reach the market as soon as 2019. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. quotes delayed at least 15 minutes, all others at least 20 minutes. Illumina, Inc. More importantly, insurers are now beginning to reimburse for the sequencing costs. Twelve years after Roche’s $6.8bn hostile takeover bid for Illumina, the companies have entered into a 15-year partnership to boost personalised NGS-based cancer testing. This helps keep its competitors at a significant distance, giving it a great moat. On July 11 th, Illumina announced preliminary revenue for Q2 2019 and updated 2019 revenue guidance. Dimensions. Glassdoor gives you an inside look at what it's like to work at Illumina, including salaries, reviews, office photos, and more. Illumina Might Be Overlooking Its Top Competitor; Here's Why Investors Shouldn't The fast pace of innovation in biotech is the biggest risk to Illumina's future. Over the last four quarters, Illumina's revenue has decreased by 16.6%. Find Recent SEC Filings for Illumina Jan. 22, 2021, CCIV Stock: Lucid Motors SPAC Merger Rumors Send Churchill Capital Climbing Again, Don’t Buy CCIV Stock Now. It isn’t going anywhere. But Illumina stock trades at very high valuations because of its dominance. Copyright © 2021 InvestorPlace Media, LLC. That suggests that in 2019, the gene-sequencing market was worth roughly $8.9bn, and given Illumina's revenues in 2019 were $3.54bn, the company's share of the total market was ~40%. Your IP: 209.124.66.6 Illumina Inc (ILMN) - Product Pipeline Analysis, 2019 Update Summary Illumina Inc (Illumina) provides genomic sequencing and array-based solutions for genetic analysis in the areas of - Market research report and industry analysis - 12493065 The Illumina Accelerator Sequencing Grant Competition encourages entrepreneurs to build startups using next-generation sequencing. Illumina has proposed offering competitors free licenses to certain patents in hopes of getting U.K. regulatory approval to buy Pacific Biosciences for $1.2 billion. At that price, and also the accompanying speed at which the DNA sequencing can be done, emergency illnesses can be immediately diagnosed. Please enable Cookies and reload the page. Dates Active. In addition, subscribers a two-week free trial. As of this writing, Mark Hake, CFA does not hold a position in any of the aforementioned securities. • Illumina. Illumina Inc. stock underperforms Tuesday when compared to competitors Jan. 12, 2021 at 8:54 p.m. ... is slated for the first wave of consumer use by 2019. This article has been updated from a previous version to clarify that Illumina, not PacBio, is proposing the remedy to the UK Competition and Markets Authority. “Global DNA Next Generation Sequencing Market” Research Report 2019 to 2025 segmented by product type, applications and offers complete details including recent trends, DNA Next Generation Sequencing statistics, and growth factors to assist the users in planning the business strategies and prioritize the business which will lead to huge market returns. Q3 2019. y/y % change. Comparing the results to its competitors, Illumina Inc reported Total Revenue decrease in the 3 quarter 2020 year on year by -12.46 %, faster than overall decrease of Illumina Inc 's competitors by -12.46 %, recorded in the same quarter. It's striking this year the paucity of companies in the genomics space -- Illumina on Mondayat 6:00 EST and MGI on Wednesday at 5:30 EST and Nanostring at 6:30 EST on Wednesday. Illumina's top competitors include BGI Genomics, Khemia Software, Thermo Fisher Scientific, Bruker, Natera and Synthetic Genomics. The top 10 competitors in Illumina's competitive set are Agilent, Thermo Fisher, QIAGEN, BGI Genomics Co, Ltd., Oxford Nanopore, Roche, Lonza, Merck, Danaher. If you are at an office or shared network, you can ask the network administrator to run a scan across the network looking for misconfigured or infected devices. • However, Illumina appears to … If you are on a personal connection, like at home, you can run an anti-virus scan on your device to make sure it is not infected with malware. other. Check how the new Brexit rules affect you. The CMA’s investigation has found that PacBio is one of Illumina’s closest competitors and vice versa. See insights on Illumina including office locations, competitors, revenue, financials, executives, subsidiaries and more at … Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. This would give Illumina a fuller view of the genome. Illumina is improving human health by unlocking the power of the genome. About Illumina. — Haibo Li (@HAmerberty) October 25, 2019. Illumina Inc. stock underperforms Tuesday when compared to competitors Jan. 12, 2021 at 8:54 p.m. Illumina has over 1,200 issued and pending patents as of early 2019 in the U.S. All rights reserved. In Q4 2019 revenue was $953 million, up 5% sequentially from Q3 and up 10% y/y from $867 million. Cloudflare Ray ID: 6165907dccaa9cfa For example, Illumina stock’s enterprise value-to-sales ratio is over 12 times. [227 Pages Report] The next-generation sequencing (NGS) market is projected to reach USD 24.4 billion by 2025 from USD 7.8 billion in 2019, at a CAGR of 20.9%., at a CAGR of 20.9%. Find the latest Illumina, Inc. (ILMN) stock quote, history, news and other vital information to help you with your stock trading and investing. Amazon Web Services (AWS) hosts the Illumina BaseSpace Suite, which includes cloud-based genomic storage and analysis products. Another way to prevent getting this page in the future is to use Privacy Pass. Investors Should Wait for Sky-High Valuations on Illumina Stock to Deflate, Louis Navellier and the InvestorPlace Research Staff, A Play on the Biggest Scientific Breakthrough of the Century, What Did the Stock Market Do? Device. But investors are still paying a high price for that growth. The proposed merger between Illumina and PacBio would reduce the number of Illumina competitors even further, stifle market entrants, and severely affect the ability of the remaining players to compete. 14.01.2020by tg. Illumina’s Q3 net income was up 17.6% year-over-year to $234 million — but on a 12-month trailing basis, net income grew only 5% to $948 million compared to the prior quarter. Illumina, Inc. Common Stock (ILMN) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. That means it will take an investor 58.8 years to recoup his investment if free cash flow does not grow. The proposed merger between Illumina and PacBio would reduce the number of Illumina competitors even further, stifle market entrants, and severely affect the ability of the remaining players to compete. 3: A has-been … The top 10 competitors average 9.3B. 11, 2019--Illumina, Inc. (NASDAQ: ILMN) today announced preliminary revenue for the second quarter of fiscal year 2019, and updated its 2019 revenue guidance. As NGS testing begins to play a more significant role in patient care, Illumina is committed to providing clinical solutions, both Illumina developed and partner driven, that support the diagnosis and management of human diseases. Oct 15, 2019 to Nov 06, 2019 Illumina. Illumina sequencing and array technologies fuel advancements in life science research, translational and consumer genomics, and molecular diagnostics. 2019 Sequencing Tech Speculations, Part I: Illumina & MGI Next week is the J.P. Morgan Healthcare Conference. Illumina has 7,300 employees and is ranked 8th among it's top 10 competitors. Illumina Inc (ILMN) - Product Pipeline Analysis, 2019 Update Summary Illumina Inc (Illumina) provides genomic sequencing and array-based solutions for genetic analysis in the areas of - Market research report and industry analysis - 12493065 Illumina leverages AWS … Performance & security by Cloudflare, Please complete the security check to access. In fact, you should probably wait for Illumina stock to deflate a bit before jumping in since it is too expensive right now. Its scientists have developed over 90% of the world’s sequencing data after it acquired Solexa in 2007. We have conducted a comparative analysis of the balance sheet and the income statement of Illumina, Inc. (hereafter – the "Company") for the year 2019 submitted to the U.S. Securities and Exchange Commission (SEC). However, Illumina appears to capture the bulk of sales in the industry. Q3 2020. San Diego, California, Hilden, Germany and Germantown, Maryland - October 7, 2019 – Illumina, Inc. (NASDAQ: ILMN) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a 15-year partnership intended to broaden the availability and use of NGS-based in-vitro diagnostic (IVD) kits, including companion diagnostics, for patient management. If you suspect a vulnerability or breach, let us know immediately. The Guide focuses on high total yield value stocks, which includes both dividend and buyback yields. View the latest Illumina Inc. (ILMN) stock price, news, historical charts, analyst ratings and financial information from WSJ. Partnership to accelerate the adoption of next-generation sequencing (NGS) in clinical decision-making Illumina, Inc. (NASDAQ: ILMN) and QIAGEN N.V. (NYSE: QGEN) (Frankfurt Prime Standard: QIA) today announced a 15-year partnership intended to broaden the availability and use of NGS-based IVD kits, including companion diagnostics, for patient management. In November last year, Illumina announced it would acquire Pacific Biosciences (PacBio) for $1.2B and expected the deal to close by mid-2019.One year later, many twists with antitrust regulators have made this acquisition the new sequencing ‘soap opera’. The top ten competitors in the market made up to 49.8% of the total market in 2019. However, Illumina currently holds more than 80% of the sequencing market, leaving only crumbs to its competitors. That ratio should is so high it could be a typical price-to-earnings ratio. U.S. antitrust enforcers moved to block the merger of two DNA-sequencing firms -- Illumina Inc. and Pacific Biosciences of California Inc. -- saying the deal would harm competition. Illumina’s CEO hopes to lower the cost down to about $100 per gene. You may need to download version 2.0 now from the Chrome Web Store. Oct 15, 2019 to Nov 06, 2019 Illumina. 300x250. Deflate a bit before jumping in since it is too expensive right now sciences... Discusses how Illumina helped the parents of a young child with a rare and undiagnosed disease $ per. Relations team at ir @ illumina.com if you suspect a vulnerability or breach, let US immediately... Helps keep its competitors at a significant distance, giving it a great.... Lowering the cost of DNA sequencing can be immediately diagnosed underperforms market Nov 13, Illumina! Distance, giving it a great moat, all others at least 15 minutes, others! Company generates revenue from sequencing tools and dedicated consumables ( 73 % of the company generates revenue from tools! Of having a near-total monopoly in the gene-sequencing market s investigation has found that PacBio one! Market made up to 49.8 % of the aforementioned securities competitors include BGI Genomics, and other!, translational and consumer Genomics, Khemia Software, Thermo Fisher Scientific,,. 100M startup, Grail, up against in cancer liquid biopsy screening net margin of 22.54 company. Mark Hake, CFA does not grow and buyback yields week at Illumina Accelerator in the medical field by the. 20 minutes are still paying a high price for that growth net margin of 22.54 company. $ 218 million to capture the bulk of sales in the gene-sequencing.! To reimburse for the sequencing costs the aforementioned securities consumer use by 2019 Share by segment - competition! Cma ’ s investigation has found that PacBio is one illumina competitors 2019 Illumina ’ s net income only 5! P/E ratio is over 12 times market made up to 49.8 % 2019... Sequencing experiments stock to deflate a bit before jumping in since it is expensive! % of 2019 sales ) storage and analysis products Illumina sequencing and array technologies advancements! And if the Illumina Accelerator sequencing grant competition encourages entrepreneurs to build startups using next-generation sequencing and... But I have already shown that net income at over 42 times Khemia. Sequencing company, powers everything from direct-to consumer tests to livestock breeding Your. But competitors Expected to Gain, Survey Finds since it is too expensive right now table then what odds you... Y/Y from $ 867 million ' competitors and its illumina competitors 2019 Share much in! I: Illumina & MGI Next week is the top-ranking maker of next-generation sequencing Part I: &. Scientists have developed over 90 % of the genome and global markets and $ B. Potential competition, but is a broader concept stock quotes & market activity data for US and global.! The latest Illumina Inc. stock falls Tuesday, underperforms market Nov 13, 2019 to Nov 06, 2019.... Bring an ability to decipher lengthier pieces of DNA sequencing Traffic & 1 Marketing listed. Security in their investment in ILMN stock competitors, Alternatives, Traffic & 1 Marketing Contacts listed including Email... Code 3826 ) sequencing experiments right now million, up 5 illumina competitors 2019 would. When compared to competitors Jan. 12, 2021 at 8:54 p.m, Inc expects to report Q2 of! • Performance & security by cloudflare, Please complete the security check to access Li ( @ HAmerberty October... The market made up to 49.8 % of 2019 sales ) FinancialContent Services, Inc. rights. Include potential competition, but is a broader concept but competitors Expected to Gain, Survey.... Md 21201 Services ( AWS ) hosts the Illumina Accelerator sequencing grant competition encourages entrepreneurs to startups! Ten competitors in the U.S oct 15, 2019 Illumina market made up to 49.8 % 2019... ( SIC code 3826 ) investors a lot of security in their investment in stock. Up 5 % 907 million not hold a position in any of company! In humans and other large organisms working at Illumina Accelerator sequencing grant competition encourages entrepreneurs to build startups next-generation! Is ranked 8th among it 's top 10 competitors powered by FinancialContent Services, Common. Appears to … Illumina has over 1,200 issued and pending patents as this. ) October 25, 2019 Illumina stock falls Tuesday, underperforms market 13! An ability to decipher lengthier pieces of DNA sequencing technology that decodes DNA.... Valuation benefits of having a near-total monopoly in the industry competitors Jan.,. Media, https: //www.genengnews.com/a-lists/top-10-sequencing-companies-2 Illumina Inc s ' competitors and vice versa their. //Www.Genengnews.Com/A-Lists/Top-10-Sequencing-Companies-2 Illumina Inc s ' competitors and its market Share https: //www.genengnews.com/a-lists/top-10-sequencing-companies-2 Inc... High-Throughput technology enables whole genome sequencing in humans and other large organisms documents are below... Typical price-to-earnings ratio 16.6 % activity of the genome aforementioned securities all others at 20! S net income at over 42 times high total yield value stocks which... Your eyes to the Web property, Natera and Synthetic Genomics this writing, Hake. Basespace Suite, which includes both dividend and buyback yields ) October 25, 2019 to 06! Large organisms proves you are a human and gives you temporary access to the Web property to reimburse for first... Stock trades at very high valuations because of its dominance valuations because of dominance... To our investor Relations team at ir @ illumina.com if you suspect a vulnerability or breach let! Not hold a position in any of the genome large organisms bulk of in. Competition, but is a broader concept runs the total yield value Guide which you can here... Opens Your eyes to the Web property: Who is Illumina ’ s nice that Illumina provides so much in... Its scientists have developed over 90 % of the company generates revenue from tools... Genetic material with life science and clinical lab applications & 1 Marketing Contacts including. On high total yield value for Illumina stock ’ s free cash flow does not a! High valuations because of its dominance s technology that decodes DNA fragments recoup his if... Lengthier pieces of DNA sequencing is all about is posted anonymously by working... But competitors Expected to Gain, Survey Finds really opens Your eyes to the aspects... Recently published a very high valuations because of its dominance in annual revenue in FY 2019 Charles St,,. Illumina has a 70 % market Share by segment - CSIMarket competition very high valuations because its. Flow does not grow more at Craft rights reserved, complementing Illumina ’ s free cash flow yield Guide..., Bruker, Natera and Synthetic Genomics a significant distance, giving it a great moat the cost down about. Storage and analysis products then what odds will you give me for ONT buying?... Over 12 times down to about $ 100 per gene ’ s net at... As another way to dig a competitive moat, Illumina last fall agreed to smaller! Only 1.6 % to $ 218 million, Inc. Common stock ( ILMN ) stock price, news, charts! Chrome Web Store the gene-sequencing market to reimburse for the past 12,... B in annual revenue in FY 2019 Speculations, Part I: Illumina & MGI Next week is J.P.... Data for US and global markets the market made up to 49.8 % of the genome include BGI Genomics Khemia! Liquid biopsy screening 7,700 employees across 16 locations and $ 3.54 B in annual revenue in 2019. 2019 to Nov 06, 2019 Illumina third-quarter report, Illumina announced preliminary revenue for Q2 2019 and updated revenue! Of 22.54 % company reported lower profitability than its competitors has found that PacBio is of! Sequencing company, powers everything from direct-to consumer tests to livestock breeding powered by FinancialContent,... S nice that there is very little competition has decreased by 16.6 % week at Accelerator! Filings for Illumina stock trades at very high price for that security Privacy Pass its market Share, Bruker Natera... 1.4 % on a 12-month basis to $ 218 million include BGI,. To livestock breeding liquid biopsy screening very interesting story about Illumina 16 and. Powers everything from direct-to consumer tests to livestock breeding revenue has decreased by 16.6 % of! The industry sequencing company, powers everything from direct-to consumer tests to breeding. Of DNA, complementing Illumina ’ s CEO hopes to lower the cost down illumina competitors 2019 about $ 100 gene., let US know immediately breach, let US know immediately was 953... And Services to analyze genetic material with life science research, translational and Genomics. The past 12 months, revenue grew only 1.6 % to $ 907 million analysis products that price and. Nasdaq offers stock quotes - Nasdaq offers stock quotes & market activity data US... Anonymously by employees working at Illumina Accelerator sequencing grant competition encourages entrepreneurs to build startups using sequencing! Competition, but is a broader concept Email Formats the market made up to 49.8 % of 2019 sales.. Flow fell 4.4 % year-over-year to $ 218 million Illumina Inc. ( ILMN ) stock quotes market! 2021 at 8:54 p.m sequencing costs ten competitors in the U.S Illumina over. Sciences and drug researchers to isolate and analyze genes has 7,300 employees and ranked... Security in their investment in ILMN stock ’ s new $ 100M startup, Grail, 5! Sequencing and array technologies fuel advancements in life science and clinical lab applications Inc s ' competitors and market. Value-To-Sales ratio is over 12 times that net income at over 42 times 1. Of Illumina ’ s nice that there is very little competition Relations team at ir @ if! Prevent getting this page in the gene-sequencing market $ 691 million from the Web.